1. Brown GC, Brown MM, Sharma S. Doctors must define quality in care. Ophthalmol Times 1999;24:1,17-19.

2. Brown MM, Brown GC, Sharma S. Cost-effective analysis can help improve the U.S. health care system. Ocular Surgery News 2000;18:16-17.

3. Smithen L, Brown GC. Dollars and sight. The economics of ophthalmology. Curr Opin Ophthalmol 2004;15:173-180.

4. Brown GC, Brown MM, Sharma S. Comorbidities: Why public policy and health care are inextricably intertwined. Evidence-Based Ophthalmology 2004;5:128-9.

5. Ko GJ, Brown MM, Brown GC. The macroeconomics of vitreoretinal diseases. Curr Opin Ophthalmol 2005;16:184-190.

6. Brown MM, Brown GC, Brown HC, Kraushar M. The pain and suffering index. Scientific principle in a tentative arena. Evidence-Based Ophthalmology 2007;8:70-73.

7. Godshalk A, Brown GC, Brown H, Brown MM. The power of positive thinking: The mistake a doctor can make when relying solely on the power of medicine. Br J Ophthalmol 2008 Jun;92(6):783-7.

8. Ip M, Scott IU, Ho AC, Huang SS, Recchia, FM, Brown GC (Methodologist) Brown MM (Methodologist). Ophthalmic Technology Assessment. Anti-Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Prepared by the Ophthalmic Technology Assessment Committee Retina/Vitreous Panel. Ophthalmology 2008; 115:1837-1846.

9. Grumbine FL, Brown GC. Comment on “C-reactive Protein Level and Risk of Aging Macula Disorder” Authors: Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A, and de Jong PTVM. Arch Ophthalmol 2007;125(10):1396-1401. Evidence-Based Ophthalmology 2008.

10. Baker PS, Brown GC. Stem cell therapy in retinal disease. Curr Opin Ophthalmol 2009;20:175-181.

11. Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS. The economics of age-related macular degeneration. In Ho AC & Regillo CD (eds), Age-related Macular Degeneration Diagnosis and Treatment, London, Springer, 2011, pp 155-74.

12. Roth Z, Brown GC. Comment on “Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion: Standard Care Versus Corticosteroid for Retinal Vein Occlusion Study Report 10. Ophthalmology 2011;118:345-52.” Evidence-Based Ophthalmology 2011;12:134-5.

13. Brown MM, Brown GC, Leiske HB, Lieske PA. Healthcare costs, buyer alert. Curr Opin Ophthalmol. 2011 May;22(3):149-51. Review

14. Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Curr Opin Ophthalmol. 2011 May;22(3):185-9.

15. Ho AC, Scott IU, Kim SJ, Brown GC (methodologist), Brown MM (methodologist), Ip MS, Recchia FM. Ophthalmic Technology Assessment. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema. A report by the American Academy of Ophthalmology. Ophthalmology 2012; 119:2179-88.

16. Brown MM, Brown GC, Lieske HB, Lieske PA. The financial return-on-investment (ROI) of ophthalmic interventions. A new paradigm. Curr Opin Ophthalmol 2014;25:171-6.

17. Brown GC. Stopping Zika Via Specially Bred Mosquitoes. Wall St Journal, March 19-20, 2016, p A12.

18. Brown GC, Brown MM. Preauthorization. Shockett L (ed), Curr Ophthalmol Reports (in press).